Key Takeaways
- The single-use bioprocessing market is projected to grow from USD 15 billion in 2026 to USD 35.8 billion by 2035, at a CAGR of 10.1%.
- North America is the largest market, while Asia Pacific is the fastest-growing region due to rising investments in biopharmaceutical production.
- Key drivers include increasing demand for biologics and the adoption of personalized medicines and cell therapies.
Market Overview
The single-use bioprocessing market was valued at USD 13.9 billion in 2025 and is expected to reach USD 35.8 billion by 2035. This growth is driven by rising demand for biologics and biosimilars, the adoption of personalized medicines, and increased outsourcing to contract development and manufacturing organizations (CDMOs).
Key players include Sartorius AG, which held a 17.5% market share in 2025, along with Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, and Avantor Inc., together accounting for 65% of the market. These companies focus on product innovation and collaboration with the biotech sector.
The market’s growth trajectory is supported by the need for flexibility in biopharmaceutical manufacturing, as single-use systems offer reduced capital investment, lower contamination risks, and faster production timelines compared to traditional stainless-steel facilities. The preference for single-use technologies among biopharmaceutical manufacturers is also influenced by the rising production of monoclonal antibodies, vaccines, and the growing demand for advanced therapies.
Regional Insights
North America accounts for 38% of the global market, driven by a robust healthcare infrastructure and significant demand for biologics. The region saw its market increase from USD 4.2 billion in 2023 to USD 5 billion in 2025. In Europe, the market reached USD 3.8 billion, propelled by continuous investments in biomanufacturing and regulatory adherence.
Asia Pacific is rapidly expanding, projected to grow at 11.5% due to improvements in biopharmaceutical production and increasing healthcare investments. Additionally, Latin America and the Middle East & Africa are gradually enhancing their single-use bioprocessing capabilities through partnerships and investments in local production capacities.
Future Trends
Significant trends include the integration of continuous bioprocessing with single-use technologies, advancements in high-capacity single-use bioreactors, and increasing efforts towards sustainability. Companies are investing in recycling initiatives and alternative materials to address environmental concerns related to plastic waste.
As biopharmaceutical manufacturing evolves, single-use bioprocessing technologies are positioned to play a key role in supporting flexible, scalable, and cost-effective solutions across diverse applications, including monoclonal antibodies, vaccines, and cell and gene therapies. The market is expected to continue attracting investment as global demand for sophisticated biomanufacturing solutions rises.
The content above is a summary. For more details, see the source article.